Join us on Wednesday, July 22 as we rally together for the second annual GBM Awareness Day. On this day, we recognize and honor those impacted by a glioblastoma diagnosis, while elevating support for research and treatment of this unforgiving disease. In 2019, leading cancer and health organizations, including the American Brain Tumor Association, urged Congress to pass a resolution that designated a day in July to heighten awareness and commit support for research. The resolution was passed unanimously, and continues to spotlight this life-threatening condition.
GBM, or glioblastoma multiforme, is the most common, malignant primary brain tumors. Each year, an estimated 13,000 people are impacted by a GBM diagnosis in which science and medicine have yet to pinpoint a cure. For more information about glioblastoma, download our GBM factsheet.
In recognition of GBM Awareness Day, the ABTA is co-hosting Rock for Research, an online concert streamed through the ABTA Facebook page to raise funds for GBM research on July 22. With performances by tribute band, Animation – a Tribute to Rush, this one-hour concert honors Rush drummer Neil Peart, who fought against and passed away from a GBM in January 2020. All concert donations will fund a $50,000 ABTA Discovery Grant for GBM Research.
Support GBM Awareness Day
There are a number of ways you can support GBM Awareness Day with the ABTA:
Make a Donation & Join Us for Rock for Research
Join us Wednesday, July 22, 6-7 PM CT for an ABTA facebook concert fundraiser for GBM research
Give a Monthly Gift
Read how Rush band’s biggest fan is doing just that each month, in honor of the late drummer and lyricist.
About Meet Hope Head On
Because of the generous support from people like you, the ABTA has given over $35 million for brain tumor research. The ABTA’s campaign, “Meet Hope Head On,” created for our 50th anniversary, is focused on raising $50 million, in part to fund critical brain tumor research. This campaign is vital for continuing the kind of work that led to the recent FDA approval of vorasidenib, a breakthrough treatment for low-grade glioma.
